Teva’s Allergan Generics Buy Progressing, Though Timeline Might Slip
This article was originally published in The Pink Sheet Daily
Executive Summary
The companies have been hoping to close the $40.5bn deal by the end of the first quarter, but the timeline could slip into April given the size of the portfolio and pipelines under regulatory review.
You may also be interested in...
Teva’s Rosy View For A Happy Union With Allergan Generics
The company provided updated mid-term guidance for the combined company, net revenues of $26.7bn to $27.8bn and EBITDA of $10.7bn to $11.5bn in 2019. The deal is expected to close any day, management assured investors.
Metsera Launches As New Obesity Contender Flush With $290m
Clive Meanwell, former CEO of The Medicines Company, will helm the new company, backed by ARCH and other investors. He talked to Scrip about the new venture.
Teva Says The Time Is Right For Two Big Immunology Biosimilar Launches
US market access senior VP Tom Rainey talks to Scrip about the upcoming launches of biosimilar versions of Humira and Stelara.